Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
News Jun 11, 2013
The Asuragen Genomic Services Division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics (isolation/preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services).
LNA™-based microRNA real-time PCR profiling holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes. Exiqon’s microRNA real-time PCR system combines a Universal RT reaction with LNA™-enhanced PCR primers, which results in unmatched sensitivity and specificity for all sample types.
”Exiqon’s high quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners”, said Carol Berry, Sr. Vice President & GM of Asuragen Genomic Services Division.
In a comment, Sr. VP Sales & Marketing, Henrik Pfundheller of Exiqon said: “We are honored and excited to support Asuragen on the discovery of novel microRNA biomarkers” and added: “Asuragen are experts in their own right in the field of microRNA and this is a great opportunity for us to expand our presence in the U.S. market.”
Controlling mosquito-borne illnesses has historically been difficult. Scientists have turned to manipulating Wolbachia, a parasitic bacterium within mosquitoes, as a way to control the reproductive fitness of mosquito populations that transmit human disease. In a study, researchers identified a new mobile DNA element in Wolbachia, which may contribute to improved control strategies for mosquito vectors of disease.